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ABSTRACT
Introduction: Electronic monitoring devices (EMDs)
are the optimal method for collecting objective data on
inhaler use in asthma. Recent research has investigated
the attitudes of patients with asthma towards these
devices. However, no research to date has formally
considered the opinions of stakeholders and decision-
makers in asthma care. These individuals have
important clinical requirements that need to be taken
into account if EMDs are to be successfully
provisioned, making collecting their opinions on the
key barriers facing these devices a valuable process.
Methods: Three rounds of surveys in a Delphi format
were used to assess the most important pros and cons
of EMDs for asthma care in a sample of 31
stakeholders which included healthcare professionals
and members of clinical commissioning groups.
Results: The respondents identified 29 pros and 32
cons. Pros that were rated as most important included
new visual evidence to aid clinical discussions with a
patient and an increase in patient involvement and
motivation. The cons that were rated as most important
included a need for more clinical evidence of the
effectiveness of EMDs, as well as better clarity over
who has responsibilities in managing, interpreting and
discussing data with a patient.
Conclusions: The research provides a guide for EMD
developers by highlighting where these devices may
provide the most benefit as well as prioritising the key
issues that need addressing if they are to be used
effectively in everyday asthma care.
INTRODUCTION
The 2014 National Review of Asthma Deaths
found that children in the UK are still dying
from avoidable asthma attacks, with widespread
overprescribing of rescue medication a major
issue.1 Moreover, adherence rates to inhaled
steroids are below 75% in children and adoles-
cents2 and asthma still costs the National
Health Service (NHS) £1 billion a year.3
One option to improve compliance and
potentially reduce reliever overuse is elec-
tronic monitoring devices (EMDs). A recent
article referred to EMDs as the ‘21st century
gold standard’ for measuring inhaler use.4
These devices are now considered the
optimal method for accurately and reliably
recording objective data on adherence for
clinical and research practice.2 5 Recent trials
have extensively tested the validity and accur-
acy of exemplar EMDs over prolonged
periods to fully demonstrate their efﬁcacy for
use in clinical research.6 7 These devices
have also been associated with improved
adherence to inhaler therapy.8 9 However, a
recent review of currently available EMDs
highlighted a lack of consideration for
patient attitudes and stakeholder involve-
ment as key issues facing these devices going
forward.10
Initial evidence now suggests that adoles-
cents feel positively towards the monitoring
and reminding capabilities of EMDs for
helping them to demonstrate their adher-
ence and for ensuring they remember to
take their inhaler on time, with their main
concerns surrounding the bulkiness and
unusual appearance of the devices.11
However, in order to improve asthma care at
a population level, EMDs would also require
interaction from a variety of healthcare pro-
fessionals; all of whom have clinical
KEY MESSAGES
Electronic monitoring devices (EMDs) offer the
most accurate solution for recording adherence to
inhaled medication, yet little is known about the
impact they could have on the healthcare system.
This study examined the perceptions of healthcare
providers and stakeholders in asthma care towards
EMDs to examine what they believed their benefits
could be, as well as their costs and barriers. The
respondents felt that EMDs could promote better
asthma control and better health for patients, and
could also support decision-making and discus-
sions with patients during clinical consultations.
However, they also had concerns regarding cost,
data governance and felt that more evidence was
required for the effectiveness of these devices.
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requirements that need accounting for if the provision
of a medical device is to ultimately be successful.10 12 13
The stakeholders who should have access to the data
produced by EMDs have not been determined. However,
if data indicating a patient’s inhaler use was putting their
health at risk were available to a healthcare professional,
but was not acted on, they could be open to criticism for
not intervening.10 This potentially major issue is high-
lighted by a recent clinical trial using EMDs where
researchers reported ‘extreme overuse’ of β-agonists in
26% of their 152 participants, with these patients actuat-
ing 32 or more doses of reliever inhaler a day.14
To understand the potential beneﬁts and issues that
EMDs could create for the asthma care system, it is
important to involve asthma stakeholders in the intro-
duction of these devices, to help ensure they are ultim-
ately safe and effective.
The aim of the present study was to use a three-round
‘Delphi’ Survey to engage with multiple asthma care sta-
keholders and decision-makers in order to understand
what they perceive as the key pros and cons for the intro-
duction of EMDs into everyday asthma management. It
is envisaged that this information could be used to help
inform and guide the future development and successful
introduction of these devices into the NHS.
METHODS
Defining stakeholders
The targeted study population—stakeholders—can be
deﬁned as ‘individuals, organisations or communities
that have a direct interest in the process and outcomes
of a project, research or policy endeavour’.13 For this
research, stakeholders with an active interest in the
future of asthma care were identiﬁed as being:
▸ Healthcare providers: General practitioners (GPs),
nurses, consultants and pharmacists;
▸ Payers and purchasers: NHS clinical commissioning
groups (CCGs);
▸ Advisory boards: British Thoracic Society (BTS) asthma
specialist advisory group.
Recruitment
As the targeted population was anticipated to be difﬁcult
to recruit from, several routes were used for contacting
potential participants.
Paper survey
▸ Handed out to the respiratory teams at Queen’s
Medical Centre and City Hospital in Nottingham,
UK;
▸ Posted to members of local CCGs where they had
listed their interests or specialties as ‘asthma’,
‘respiratory’ or ‘paediatrics’;
▸ Sent to members of the BTS asthma specialist advis-
ory group;
▸ Handed out to delegates at the East Midlands Asthma
Day (2015) at the University of Nottingham, UK.
Online survey
▸ Emailed to doctors and nurses in Leicestershire, UK;
▸ Emailed to members of the Respiratory Effectiveness
Group (REG)—an investigator-led, not-for-proﬁt
research initiative (http://effectivenessevaluation.org);
▸ Shared on Twitter by the REG (@RespirEffect);
▸ Article and link to survey posted on the Respiratory
Futures website (http://www.respiratoryfutures.org.
uk).
Study design
A ‘Delphi’ method was chosen as it is considered an
effective research tool for collecting the judgments of
experts in different physical locations.15 Through mul-
tiple rounds of surveys, this method also allows partici-
pants to view the anonymous opinions of others, then
reﬁne and adjust their own views dependent on their
level of agreement.16 The three rounds of the Delphi
Survey used in this study are explained further.
Delphi round one
Respondents were ﬁrst given a short explanation of
EMDs for asthma in case they were unaware of their
purpose; this was carefully worded to avoid biases for or
against the devices (see online supplementary appendix
1). They were then asked to provide at least six pros and
six cons that they felt the introduction of EMDs could
have for asthma care.
Delphi round two
The responses from round one were collected and
similar points were merged. For example, responses
from participants such as ‘actual cost of device’,
‘increased inhaler costs’, ‘who funds the device?’ could
all be grouped under the same point—‘cost of devices’.
Participants were then provided with a randomised list
of every unique point that was raised in round one, for
pros and cons. Their task was then to rank each point
for its level of importance, with ‘1’ being least important
and ‘10’ being most important.
Delphi round three
The ratings from round two were then collated and ana-
lysed. Lists of the pros and cons ranked by their rated
level of importance were then presented back to partici-
pants in round three and they were asked for ﬁnal quali-
tative feedback on whether they agreed with the order, if
they felt anything was missing, and if they felt that their
views towards EMDs had changed over the process.
Materials
Surveys were available in paper and online formats to
allow for different methods of contacting potential parti-
cipants. The online version of the survey was run using
Qualtrics (https://www.qualtrics.com). The information
included in both versions of the survey was the same.
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RESULTS
Study population
It was not possible to accurately estimate the number of
potential participants compared with the number who
responded because of the multiple different routes of
recruitment that were used.
Participants recruited into the study all took part in
round one of the Delphi, with dropout meaning a
reduced number responded to round two and a further
reduced number completed round three. Details of the
sample at each stage are provided in table 1. Although
there is no concrete recommendation for the sample
size required for a Delphi Study, they are rarely con-
ducted with <10 participants.17 The sample used here
therefore falls within recommended guidelines.
Round one results
After collecting the responses for round one, the 154
pros and 159 cons of EMDs provided by the respondents
were analysed to ﬁnd occasions where different partici-
pants had raised the same point. Responses were then
grouped and given names to accurately report every
unique point raised by the participants.
A total of 29 pros and 32 cons were found from the
data in survey one and are displayed in tables 2 and 3,
respectively. The number of times each point was raised
independently is shown in the tables and provides an
indication of the factors that were brought up most
frequently.
Round two results
Participants in round two rated each point for its relative
importance on a scale where 10 was most important and
1 was least important. To analyse these data, the number
of 10, 9 and 8s were counted for each issue. The most
important issues were then selected using the following
criteria:
1. Total number of 10 and 9s;
2. If still equal between two or more issues—the total
number of 10, 9 and 8s.
This calculation was done for the full sample of parti-
cipants (N=18) as well as for the two largest subgroups—
consultants (n=8) and nurses (n=6). The top ﬁve most
important pros and cons for the full sample are shown
in tables 4 and 5, with the data for consultants and
nurses shown in table 6.
As can be observed from the data, the points rated
most important in round two are not the same points
that were raised most frequently in round one.
‘Evidence of the effectiveness of EMDs is required’ was
raised on only four occasions in the ﬁrst round of the
survey, yet was given a rating of 9 or 10 by half of the
sample, making it the most important con facing EMDs,
according to the results.
For consultants and nurses, there was a difference
between the points they rated as most important. The
pros rated important by the consultants appear to focus
more on supporting the consultation process; through
providing them with visual evidence to show patients—
such as graphs on their adherence over a period of
time, and by allowing them to make more informed
decisions about a patient’s care plan. In contrast, the
pros rated highly by nurses focus more on the patient
and their health, asthma outcomes and medication use.
For cons, consultants rated ‘evidence of effectiveness of
EMDs is required’ as most important, while nurses were
more concerned with where responsibility would lie for
downloading, interpreting and discussing the data with
patients.
Interestingly, ‘records actuation but not inhalation,
technique, nor identiﬁes if canister is empty or inhaler
is shared’ was rated as the second most important con
overall (see table 5), yet was not rated in the top three
cons for either consultants or nurses (see table 6). This
was due to high ratings of 10 from two GPs, who were a
smaller participant group.
Round three results
In round three, the remaining 10 participants reviewed
the ranked list of pros and cons formed from the ratings
given in round two and provided their ﬁnal comments
and feedback.
Respondents provided new feedback on some of the
pros and cons that had been formed in round one. For
example, one consultant felt that ‘better asthma control
and improved quality of life’ was not necessarily “…
implicit in the use of smart inhalers [EMDs ]: it is what
we hope will happen….” The same consultant felt that a
pro that was missing from the list and should be consid-
ered important would be “Collecting data for making
large scale decisions in terms of health services delivery
and research.” Furthermore, the same consultant felt
that a con that was currently missing but could be con-
sidered related to ‘cost of devices’ was ‘institutional pro-
curement process’ and stated, “it is a complete pain to
Table 1 Sample size across the three rounds of the Delphi Survey with occupation demographics included
Delphi round Total Consultants GPs Nurses Pharmacists
No occupation
provided
CCG/advisory board members
(from the existing sample)
Round one 31 8 6 9 1 7 5
Round two 18 8 3 6 1 0 4
Round three 10 3 1 6 0 0 1
CCG, clinical commissioning group; GP, general practitioner.
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acquire things that aren’t either drugs for a patient or
equipment for the institute.”
One GP disagreed with EMDs being regarded as a
‘paternalistic approach’ and instead commented, “this is
genuinely treating patients as an adult and empowering
them.” The same participant felt that ‘data overload’
should be rated as more important, stating that this is “a
genuine fear which needs to be addressed.” Elsewhere, a
nurse felt that more should be made of the technology
appealing to patients, “…particularly as we are often
dealing with a younger adult age group.”
Many of the respondents spoke about how taking part
in the research had changed their views towards EMDs.
For example, one consultant said that their attitude had
moved from “not at all interested [in using EMDs] to
possibly interested for selected patients.” Whereas a
nurse stated that their views were different because they
now had a “…better understanding about how they
work and the beneﬁts to the patients.” However, another
nurse who had previous experience with EMDs still had
reservations about the devices, and believed they could
often be prone to errors and faults, stating “these can be
frustrating for both patients and clinicians, and may
cause problems when reviewing results.”
Overall review of the pros and cons associated with
electronically monitoring inhaler use
Pros and cons were obtained which relate to the patient
and their health, the job and workload of the clinician,
advancing asthma research and the practicalities of
EMDs more generally. An in-depth review of these
factors is provided here, focusing on the factors where
the most in-depth supporting quotes from participants
were received.
Patient-related factors
Participants identiﬁed several pros and cons of EMDs
that could directly affect the health and care of patients
with asthma. The factors where the most in-depth com-
ments were received are discussed here and a full list is
provided in table 7.
The respondents often spoke about how EMDs could
have the potential to improve adherence, with some
continuing to describe how this could lead to improved
asthma control and quality of life. Comments included
“compliance enhanced,” “Effective use of treatment,”
“more likely to comply” and “Improved care, because of
increased adherence.” Many of the respondents felt that
the reminders an EMD could provide would have a
Table 2 The 29 pros participants gave for electronically monitoring inhaler use, with the number of times each point was
raised
Pros Sum
1. An accurate record of adherence for clinicians/nurses/general practitioners to use in auditing and review 24
2. Reminding the patient to use their inhaler 17
3. For identifying patterns of inhaler use, for example, days, times, school, holidays, etc 12
4. Aiding discussions between the clinician and patient, for example, visual evidence 11
5. Improve compliance 8
6. Reducing costs through less wasted medication and less time in hospital 8
7. Relating an accurate record of a patient’s inhaler use to their health outcomes and asthma control 7
8. Data for research 6
9. Patient can see their inhaler use from home and know if they are underusing/overusing 6
10. Patient has proof of their adherence to share with their clinician—increasing trust 6
11. Increase patient involvement and motivation for treating their condition 5
12. More informed decision-making for clinicians 5
13. Better asthma control and improved quality of life 4
14. Adding the ability to alert when the inhaler is about to run out would be beneficial 3
15. Adding the ability to monitor inhaler technique would be beneficial 3
16. Can be used to identify inhaler types that are less likely to be used—to ultimately find the most widely accepted
and used inhaler types
3
17. Increasing patient independence, accountability and self-management for their asthma 3
18. Parents can check on their child’s inhaler use 3
19. The patient’s awareness of monitoring by their clinician may improve their compliance 3
20. ‘Cool’ technology may appeal to patients 2
21. Could reduce exacerbations 2
22. GPS would be beneficial in identifying triggers for a patient’s asthma, for example, pollen, pollution 2
23. Could be used with other monitoring techniques, for example, peak flow 1
24. Helpful for identifying dose dumping 1
25. Increasing patient confidence in their care 1
26. Long term—could be used to develop bio feedback 1
27. Promote competition 1
28. Useful data for emergency situations 1
29. Useful to monitor adherence of different groups of patients on different treatments 1
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direct effect on how often patients were using their inha-
lers. For example, one nurse stated, “The EMD would
be useful in patients who forget to take their inhaler,
and acts as a reminder, and get them into a habit of
taking their inhaler regularly,” whereas another nurse
commented, “Some children would love the fact that
devices are being used to remind them….”
Participants also commented on the positive effect
that EMDs could have for motivating patients and creat-
ing a sense of independence and accountability for their
condition. A nurse commented that “ the patients can
individualise the EMD by selecting their own tune and
time of the alarm, which by involving the patient in
choice may increase adherence to medication” while a
pharmacists and CCG member stated “Uploadable
results may improve patient involvement and interest in
their treatment.” Some comments were also received
from respondents who felt that the technology could be
an attractive feature, such as “The device may appeal to
patients who like the new technology and gadget feel.”
Table 3 The 32 cons participants gave for electronically monitoring inhaler use, with the number of times each point was
raised
Cons Sum
1. Cost of devices 32
2. Bulkiness and appearance may put patients off 14
3. Patient may not like being ‘watched’ 12
4. Accuracy and reliability of the device, as well as potential technical issues 9
5. Concerns over the time and workload this would add to the consultation process 9
6. Concerns if this is only compatible with MDIs 7
7. Records actuation but not inhalation, technique, nor identifies if canister is empty or inhaler is shared 7
8. Whose responsibility is downloading, processing and interpreting the data and discussing with patients? 7
9. How is data stored and who has access? 6
10. An EMD may be required for more than one inhaler per patient 5
11. Evidence of the effectiveness of EMDs is required 4
12. Cleaning and maintenance of the device 3
13. Concerns about the role of pharma companies 3
14. Could interfere with inhalation technique or not be compatible with spacer 3
15. Data overload 3
16. Ease of use—another thing patients have to learn 3
17. Elderly patients may struggle with the technology or have a negative attitude towards it 3
18. May make no difference to already unengaged patients 3
19. May put patients off coming to clinic particularly if they have failed 3
20. Paternalistic approach 3
21. Added cost/time/workload of training clinicians and staff on how to use device, how to teach patients and how to
interpret results
2
22. Are there better alternatives, for example, Tele-health or Medication Possession Ratio (MPR)? 2
23. Over-reliance on data—also need to determine reasons for non-adherence 2
24. Patient may forget to bring device with them to clinic 2
25. Patient resistance or refusal to use the device 2
26. Patients may find the reminders a nuisance 2
27. Bad for the environment—plastic and batteries 1
28. Could create potential conflicts between the patient and their clinician or parents 1
29. Many who get this device may do so as there are adherence concerns and therefore will show (inevitably) that
adherence is poor
1
30. More benefits for researchers than patients, meaning patients may fail to see worth 1
31. Non-adopters lead to selection biases 1
32. This will not address intentional non-adherence 1
EMD, electronic monitoring device.
Table 4 The top five pros rated most important by the participants (10=most important, 1=least important)
Five most important pros (N=18) 10s, 9s 10s, 9s, 8s
1. Better asthma control and improved quality of life 9 13
2. Aiding discussions between the clinician and patient, for example, visual evidence 8 15
3. The patient’s awareness of monitoring by their clinician may improve their compliance 7 14
4. Increase patient involvement and motivation for treating their condition 7 12
5. More informed decision-making for clinicians 7 11
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Participants also felt that the data recorded by EMDs
could foster a trusting relationship between the patient
and their clinician. For example, one respiratory consult-
ant stated, “patients know that clinicians ‘believe ’ them
re concordance” while a GP similarly said that it “may
encourage asthma review as have ‘done well ’ and will
receive praise.” Some respondents also felt that a patient
simply being aware of their inhaler use being monitored
could have a positive impact, with a respiratory consult-
ant commenting, “Positive observation effect: people
won’t know when they are being watched so are more
likely to behave.”
While participants recognised the beneﬁt EMDs could
have for patients with asthma, they equally had concerns
for the potential barriers that may need to be addressed
or overcome for beneﬁts to come to fruition.
First, many comments pertaining to the bulkiness and
size of the device were received. One GP and CCG
member stated that the “EMD may make the whole
inhaler bulky—not user friendly and may discourage
patients to clip it onto their inhaler,” while a respiratory
consultant with ﬁrst-hand experience of EMDs warned,
“they were not popular with patients, many liked the
idea but found the reality of the device too bulky and
cumbersome.” Others additionally felt that the usability
of the device could be a potential issue, with a nurse
and CCG member commenting, “this may be another
device the patient has to get to grips with along with the
various types of inhaler they may be using.” This could
be a particular problem in older patients; a GP and
CCG member asked, “Are they accessible to the older
generation who may not be quite so ok with using
technology?”
As opposed to the potential beneﬁts for some patients
in encouraging good adherence, respondents felt there
was potential for EMDs to have a negative effect on a
patient’s attitude. A GP commented, “Intrusion may not
be well received—‘Big Brother’” and a nurse stated,
“people are highly resistant to being watched.” Some felt
this could even effect whether patients attend clinic
Table 5 The top five cons rated most important by the participants (10=most important, 1=least important)
Five most important cons (N=18)
10s,
9s
10s, 9s,
8s
1. Evidence of the effectiveness of electronic monitoring devices is required 9 11
2. Records actuation but not inhalation, technique, nor identifies if the canister is empty or the inhaler is
shared
6 11
3. Whose responsibility is downloading, processing and interpreting the data and discussing with
patients?
6 10
4. Could interfere with inhalation technique or not be compatible with spacer 6 9
5. Patient may forget to bring device with them to clinic 6 7
Table 6 The top three most important pros and cons for the two occupation groups with the largest samples—consultants
and nurses (10=most important, 1=least important)
10s,
9s
10s, 9s,
8s
Three most important pros
Consultants (n=8)
Aiding discussions between the clinician and the patient, for example, visual evidence 5 7
More informed decision-making for clinicians 5 6
The patient’s awareness of monitoring by their clinician may improve their compliance 4 5
Nurses (n=6)
Better asthma control and improved quality of life 4 5
Improve compliance 3 5
Relating an accurate record of a patient’s inhaler use to their health outcomes and asthma control 3 3
Three most important cons
Consultants (n=8)
Evidence of the effectiveness of electronic monitoring devices is required 4 4
Patient may not like being ‘watched’ 2 5
Could interfere with inhalation technique or not be compatible with spacer 2 4
Nurses (n=6)
Whose responsibility is downloading, processing and interpreting the data and discussing with
patients?
4 5
An electronic monitoring device may be required for more than one inhaler per patient 4 4
Accuracy and reliability of the device, as well as potential technical issues 4 4
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visits, with a respiratory consultant stating, “Patients may
feel their clinician is checking up on them and may be
put off coming for review.”
Comments were also received stating that this was a
“paternalistic approach to medicine” and a “restriction
of a patient’s autonomy.” However, this was not a univer-
sal opinion.
Clinician-related factors
With the data collected by an EMD having wide-ranging
uses and implications for a clinician and their care of
patients; the participants identiﬁed many different pros
and cons related to healthcare professionals. The factors
where the most in-depth comments were received are
discussed here and a full list is provided in table 8.
Many of the participants spoke about the devices pro-
viding an accurate record of adherence that could be
used by a clinician in their auditing of a patient. For
example, one respiratory consultant said that EMDs
would create “a tool to monitor actual adherence
achieved against the goals previously agreed.” Some
respondents speciﬁcally mentioned how this would be a
Table 7 The pros and cons that are related to the patient
Patient-related pros Patient-related cons
▸ Reminding the patient to use their inhaler ▸ Bulkiness and appearance may put patients off
▸ Improve compliance ▸ Patient may not like being ‘watched’
▸ Patient can see their inhaler use from home and
know if they are underusing/overusing
▸ An electronic monitoring device may be required for more than one
inhaler per patient
▸ Patient has proof of their adherence to share with
their clinician—increasing trust
▸ Ease of use—another thing patients have to learn
▸ Increase patient involvement and motivation for
treating their condition
▸ Elderly patients may struggle with the technology or have a negative
attitude towards it
▸ Better asthma control and improved quality of life ▸ May make no difference to already unengaged patients
▸ Adding the ability to alert when the inhaler is about
to run out would be beneficial
▸ May put patients off coming to clinic particularly if they have failed
▸ Increasing patient independence, accountability
and self-management for their asthma
▸ Paternalistic approach
▸ Parents can check on their child’s inhaler use ▸ Patient may forget to bring the device with them to clinic
▸ Patient’s awareness of monitoring by their clinician
may improve their compliance
▸ Patient resistance or refusal to use the device
▸ ‘Cool’ technology may appeal to patients ▸ Patient may find the reminders a nuisance
▸ Could reduce exacerbations ▸ Could create potential conflicts between the patient and their
clinician or parents
▸ Increasing patient confidence in their care ▸ Many who get this device may do so as there are adherence
concerns and this will show (inevitably) that adherence is poor
▸ Promote competition ▸ More benefits for researchers than patients, meaning patients may
fail to see worth
▸ This will not address intentional non-adherence
Table 8 The pros and cons that are related to the clinician
Clinician-related pros Clinician-related cons
▸ An accurate record of adherence for clinicians/nurses/
general practitioners to use in auditing and review
▸ Concerns over the time and workload this would add to the
consultation process
▸ For identifying patterns of inhaler use, for example,
days, times, school, holidays, etc
▸ Whose responsibility is downloading, processing and
interpreting the data and discussing with patients?
▸ Aiding discussions between the clinician and the
patient, for example, visual evidence
▸ Data overload
▸ Relating an accurate record of a patient’s inhaler use to
their health outcomes and asthma control
▸ Added cost/time/workload of training clinicians and staff on how
to use device, how to teach patients and how to interpret
results
▸ More informed decision-making for clinicians ▸ Over-reliance on data—also need to determine reasons for
non-adherence
▸ GPS would be beneficial in identifying triggers for a
patient’s asthma, for example, pollen, pollution
▸ Helpful for identifying dose dumping
▸ Useful data for emergency situations
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more accurate estimate of inhaler use than asking the
patient directly, with one CCG member saying it would
“improve assessment of compliance—rather than rely on
a patient telling their clinician.”
Participants then spoke of how this accurate record of
adherence would be useful for identifying patterns of
use, with one nurse and CCG member stating, “Being
able to demonstrate patterns of use… is particularly
important for patients who forget to use their inhalers
or are unsure of the frequency of use for ‘as required’
inhalers.” Other participants then additionally spoke
about how a true record of inhaler use could be related
to health outcomes and asthma control, “the data could
be used to establish if their asthma control is poor due
to reduced adherence to medication or their medication
requires escalation to improve control.”
Furthermore, participants commented on how this
detailed picture of a patient’s medication management
would ultimately lead to more informed decision-
making, with one respiratory consultant stating it would
provide “objective data for clinicians to make decisions,
not report” and another consultant adding, “Changes in
medication…could be based on accurate reports of
current medication regimen administered.” There was
also a shared feeling that the data could be used to aid
discussions between a clinician and patient. One nurse
provided the insightful comment that “We do practice
open conversations, but seeing things written down or
pictorially presented may be more effective in devising
an action plan together.”
Much the same as with factors related to the patient,
the participants had concerns about the potential bar-
riers EMDs may have to overcome to provide true
beneﬁt for clinicians.
First, there were concerns expressed by participants
about the time and added workload EMDs could create.
One nurse said, “The time to download and examine
the data collected from the EMDs in clinic may be
limited,” while a GP and CCG member stated, “Doctors
don’t have enough time to follow up adherence.”
Questions were also asked about who should actually
take responsibility for downloading, processing and
interpreting the data and then discussing it with the
patient. One participant stated, “some clinicians may not
appreciate that the time taken to discuss results together
is actually saving time in the future. Who is the best pro-
fessional to discuss data with patient/family? GP, nurse,
specialist doctor or other?” Related to this was a
comment about the cost of training, “clinicians will
require training on the use and interpreting of the
results.”
Research-related factors
With a proportion of the recruited sample having strong
ties to academic research, points were raised in relation
to using EMDs for asthma research going forward, as
well as further research required now. The factors where
the most in-depth comments were received are discussed
here and a full list is provided in table 9.
One respiratory consultant felt that EMDs could be
useful “to monitor concordance of different groups of
patients on different treatment regimens” to examine
how adherence varies from medication to medication.
Along a similar line, a GP commented that EMDs could
be used to “identify devices which are less likely to be
used and weed them out, and which ones are easier and
more likely to be used.”
Another GP spoke of the potential for location moni-
toring, stating it could be useful “to identify triggers…
but may not be accurate if trigger is mobile.” Elsewhere,
a nurse recognised the beneﬁt EMDs could have for
research more generally, “to validate study results by
showing compliance with a particular treatment.”
Although research exists that demonstrates the accur-
acy of EMDs, some participants felt that more evidence
is needed. One respiratory consultant asked, “Has the
data they collect been validated? Personal use with an
older generation of these devices [on a research study]
has been poor. Ranged from recording puffs for patients
who had never used them to recording nothing at all
when we knew they were deﬁnitely used.” Another par-
ticipant asked, “does the EMD have a sustainable effect
as a reminder?”
Practical factors
Many of the points raised by the participants were
applicable to the healthcare industry in general and
focused on the practicalities of the devices. The factors
where the most in-depth comments were received are
discussed here and a full list is provided in table 10.
Table 9 The pros and cons that are related to research
Research-related pros Research-related cons
▸ Data for research ▸ Evidence of the effectiveness of electronic
monitoring devices is required
▸ Can be used to identify inhaler types that are less likely to be
used—to ultimately find the most widely accepted and used inhaler
types
▸ Are there better alternatives, for example,
Tele-health or Medical Possession Ratio (MPR)?
▸ Long-term could be used to develop bio-feedback ▸ Non-adopters lead to selection biases
▸ Useful to monitor adherence of different groups of people on
different treatments
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Some participants recognised that better adherence
and asthma control could lead to a reduction in hospital
admissions, wasted medication and healthcare costs.
One nurse and CCG member stated, “Ensuring better
adherence to inhaler treatment will have a positive
effect on wider health economics, eg, more patients
being well managed.”
While the potential positive ﬁnancial effects of EMDs
were recognised by some participants, many had con-
cerns about the initial cost of the devices. One nurse
asked, “How much do they cost? Is this cost incurred by
the department, GP practise or patient?” while a GP
stated, “The cost of each EMD may be expensive and
may be limited to the more severe asthmatics having
them.” The points were typically questioning of the cost
rather than dismissive of it, highlighting a need for
better clarity on initial costings versus potential savings.
There were also some concerns regarding the reliabil-
ity of the devices with a nurse asking, “How robust are
they? They need to be up to being thrown around and
chucked in bags or drawers and left in wet steamy bath-
rooms!” Participants also raised issue with the fact the
devices typically only record actuation and do not
record inhalation, technique nor detect if the inhaler is
shared. One participant stated, “I would want assurance
that the device was not open to abuse, eg, removable in
order to conceal overuse or inhaler sharing, or pressing
device and not inhaling.”
DISCUSSION
Implications for EMDs and asthma care
By examining the pros and cons of electronically moni-
toring inhaler use from the perspective of stakeholders,
this research provides a knowledge base for EMD develo-
pers. The data gathered should be used as a guide to
help inform future directions for improving the design of
the devices and for providing greater clarity to stake-
holders for how they could realistically be integrated into
everyday asthma care. For example, participants here
expressed concerns about the time these devices could
add to the consultation process, as well as the training
that would be required to use them. EMD developers
should work alongside healthcare professionals to ensure
devices and accompanying software are simple and intui-
tive to reduce their impact on consultation time.
Limitations and future research
The sample used here was sufﬁcient to gather a compre-
hensive list of the main pros and cons associated with
EMDs, but was limited in the number of participants
who gave ratings for each point’s importance.
Furthermore, the sample contained more consultants
and GPs than nurses, meaning a balance of different
viewpoints may not have been fully achieved. Future
research should look to distribute the list of pros and
cons to a larger sample, such as a respiratory organisa-
tion, to gather a larger data set for the issues stake-
holders rate as most crucial to address.
Future research should also address data governance.
While participants here did question whose responsibil-
ity it would be to download, interpret and discuss the
data with patients, this should be examined further.
Working with stakeholders to establish how data could
realistically be handled and managed within the NHS
will help to reduced fears of ‘data overload’ and ensure
that the data can be used appropriately and effectively
to ultimately beneﬁt patient care.
CONCLUSION
Through collecting the views of stakeholders with a
direct interest in the future of asthma care, a compre-
hensive list of the pros and cons associated with introdu-
cing EMDs into the NHS has been obtained. The
stakeholders raised points relating to the care and well-
being of patients, the work of a clinician, research and
more practical factors such as device reliability and cost.
Factors that particularly need addressing by EMD develo-
pers include assurances over the cost of the devices and
data governance. The ﬁndings provide a guide for
where EMDs could add most beneﬁt and additionally
identify the key issues and challenges that need to be
overcome for their introduction to be successful.
Table 10 The pros and cons that are related to practical factors
Practical-related pros Practical-related cons
▸ Reducing costs through less wasted medication
and less time in hospital
▸ Cost of devices
▸ Could be used with other monitoring techniques,
for example, peak flow
▸ Accuracy and reliability of the device, as well as potential technical
issues
▸ Concerns if this is only compatible with MDIs
▸ Records actuation but not inhalation, technique, nor identifies if
canister is empty or inhaler is shared
▸ How is data stored and who has access?
▸ Cleaning and maintenance of the device
▸ Concerns about the role of pharma companies
▸ Could interfere with inhalation technique or not be compatible with
spacer
▸ Bad for the environment—plastic and batteries
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